{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T16:01:30Z","timestamp":1776787290535,"version":"3.51.2"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000002","name":"national institutes of health","doi-asserted-by":"publisher","award":["R25 GM56847"],"award-info":[{"award-number":["R25 GM56847"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"national institutes of health","doi-asserted-by":"publisher","award":["P30 DK026743"],"award-info":[{"award-number":["P30 DK026743"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"national natural science foundation of china","doi-asserted-by":"publisher","award":["81603204"],"award-info":[{"award-number":["81603204"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012269","name":"science and technology innovative research team in higher educational institutions of hunan province","doi-asserted-by":"publisher","award":["2018035"],"award-info":[{"award-number":["2018035"]}],"id":[{"id":"10.13039\/501100012269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005496","name":"american foundation for pharmaceutical education","doi-asserted-by":"publisher","award":["Predoctoral Fellowship"],"award-info":[{"award-number":["Predoctoral Fellowship"]}],"id":[{"id":"10.13039\/100005496","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1007\/s11095-021-03105-w","type":"journal-article","created":{"date-parts":[[2021,11,2]],"date-time":"2021-11-02T20:39:24Z","timestamp":1635885564000},"page":"1639-1644","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Analyzing Potential Intestinal Transporter Drug-Drug Interactions: Reevaluating Ticagrelor Interaction Studies"],"prefix":"10.1007","volume":"38","author":[{"given":"Shuaibing","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jasleen K.","family":"Sodhi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9678-2371","authenticated-orcid":false,"given":"Leslie Z.","family":"Benet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,11,2]]},"reference":[{"issue":"9","key":"3105_CR1","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1124\/dmd.110.032250","volume":"38","author":"R Teng","year":"2010","unstructured":"Teng R, Oliver S, Hayes MA, Butler K. Absorption, distribution, metabolism, and excretion of ticagrelor in healthy subjects. Drug Metab Dispos. 2010;38(9):1514\u201321.","journal-title":"Drug Metab Dispos"},{"issue":"11","key":"3105_CR2","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1007\/s40262-015-0290-2","volume":"54","author":"R Teng","year":"2015","unstructured":"Teng R. Ticagrelor: Pharmacokinetic, pharmacodynamic and pharmacogenetic profile: An update. Clin Pharmacokinet. 2015;54(11):1125\u201338.","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"3105_CR3","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1124\/dmd.110.037143","volume":"39","author":"D Zhou","year":"2011","unstructured":"Zhou D, Andersson TB, Grimm SW. In vitro evaluation of potential drug-drug interactions with ticagrelor: cytochrome P450 reaction phenotyping, inhibition, induction, and differential kinetics. Drug Metab Dispos. 2011;39(4):703\u201310.","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"3105_CR4","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1208\/s12248-015-9845-2","volume":"18","author":"CM Hosey","year":"2016","unstructured":"Hosey CM, Chan R, Benet LZ. BDDCS predictions, self-correcting aspects of BDDCS assignments, BDDCS assignment corrections, and classification for more than 175 additional drugs. AAPS J. 2016;18(1):251\u201360.","journal-title":"AAPS J"},{"key":"3105_CR5","unstructured":"FDA. ticagrelor approved pacakage. [cited; Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2011\/022433Orig1s000ChemR.pdf. 2011"},{"issue":"6","key":"3105_CR6","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1111\/fcp.12219","volume":"30","author":"N Marsousi","year":"2016","unstructured":"Marsousi N, Doffey-Lazeyras F, Rudaz S, Desmeules JA, Daali Y. Intestinal permeability and P-glycoprotein-mediated efflux transport of ticagrelor in Caco-2 monolayer cells. Fundam Clin Pharmacol. 2016;30(6):577\u201384.","journal-title":"Fundam Clin Pharmacol"},{"key":"3105_CR7","doi-asserted-by":"crossref","unstructured":"Liu S, Wang Z, Hou L, Tian X, Zhang X, Cai W. Predicting the effect of tea polyphenols on ticagrelor by incorporating transporter-enzyme interplay mechanism Chem Biol Interact. 2020;330:109228.","DOI":"10.1016\/j.cbi.2020.109228"},{"issue":"29","key":"3105_CR8","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1093\/eurheartj\/ehv116","volume":"36","author":"C Varenhorst","year":"2015","unstructured":"Varenhorst C, Eriksson N, Johansson A, Barratt BJ, Hagstrom E, Akerblom A, et al. Effect of genetic variations on ticagrelor plasma levels and clinical outcomes. Eur Heart J. 2015;36(29):1901\u201312.","journal-title":"Eur Heart J"},{"key":"3105_CR9","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1208\/s12248-020-00469-6","volume":"22","author":"JK Sodhi","year":"2020","unstructured":"Sodhi JK, Benet LZ. The necessity of using changes in absorption time to implicate intestinal transporter involvement in oral drug-drug interactions. AAPS J. 2020;22:111.","journal-title":"AAPS J"},{"issue":"10","key":"3105_CR10","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1007\/s11095-020-02927-4","volume":"37","author":"JK Sodhi","year":"2020","unstructured":"Sodhi JK, Liu S, Benet LZ. Intestinal efflux transporters P-gp and BCRP are not clinically relevant in apixiban disposition. Pharm Res. 2020;37(10):208.","journal-title":"Pharm Res"},{"issue":"5","key":"3105_CR11","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1007\/s11095-021-03039-3","volume":"38","author":"W Kou","year":"2021","unstructured":"Kou W, Sodhi JK, Wu X, Benet LZ. Investigating intestinal transporter involvement in rivaroxaban disposition through examination of changes in absorption. Pharm Res. 2021;38(5):795\u2013801.","journal-title":"Pharm Res"},{"key":"3105_CR12","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s40262-020-00926-7","volume":"60","author":"JK Sodhi","year":"2021","unstructured":"Sodhi JK, Huang CA, Benet LZ. Volume of distribution is unaffected by metabolic drug-drug interactions. Clin Pharmacokinet. 2021;60:205\u201322.","journal-title":"Clin Pharmacokinet"},{"key":"3105_CR13","doi-asserted-by":"crossref","unstructured":"Grover A, Benet LZ. Effects of drug transporters on volume of distribution. AAPS J. 2009;11:250-61.","DOI":"10.1208\/s12248-009-9102-7"},{"key":"3105_CR14","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1002\/jps.2600680845","volume":"68","author":"LZ Benet","year":"1979","unstructured":"Benet LZ, Galeazzi RL. Noncompartmental determination of the steady-state volume of distribution. J Pharm Sci. 1979;68:1071\u20134.","journal-title":"J Pharm Sci"},{"issue":"1","key":"3105_CR15","doi-asserted-by":"publisher","first-page":"30","DOI":"10.3109\/21556660.2013.785413","volume":"2","author":"R Teng","year":"2013","unstructured":"Teng R, Butler K. Effect of the CYP3A inhibitors, diltiazem and ketoconazole, on ticagrelor pharmacokinetics in healthy volunteers. J Drug Assess. 2013;2(1):30\u20139.","journal-title":"J Drug Assess"},{"issue":"4","key":"3105_CR16","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1007\/s00228-012-1436-x","volume":"69","author":"R Teng","year":"2013","unstructured":"Teng R, Mitchell P, Butler K. Effect of rifampicin on the pharmacokinetics and pharmacodynamics of ticagrelor in healthy subjects. Eur J Clin Pharmacol. 2013;69(4):877\u201383.","journal-title":"Eur J Clin Pharmacol"},{"issue":"8","key":"3105_CR17","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s40261-014-0205-2","volume":"34","author":"R Teng","year":"2014","unstructured":"Teng R, Kujacic M, Hsia J. Pharmacokinetic interaction study of ticagrelor and cyclosporine in healthy volunteers. Clin Drug Invest. 2014;34(8):529\u201336.","journal-title":"Clin Drug Invest"},{"issue":"6","key":"3105_CR18","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1111\/bcp.12026","volume":"75","author":"MT Holmberg","year":"2013","unstructured":"Holmberg MT, Tornio A, Joutsi-Korhonen L, Neuvonen M, Neuvonen PJ, Lassila R, et al. Grapefruit juice markedly increases the plasma concentrations and antiplatelet effects of ticagrelor in healthy subjects. Br J Clin Pharmacol. 2013;75(6):1488\u201396.","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"3105_CR19","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1002\/cpt.1828","volume":"108","author":"JK Sodhi","year":"2020","unstructured":"Sodhi JK, Benet LZ. A simple methodology to differentiate changes in bioavailability from changes in clearance following oral dosing of metabolized drugs. Clin Pharmacol Ther. 2020;108(2):306\u201315.","journal-title":"Clin Pharmacol Ther"},{"key":"3105_CR20","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s10928-019-09626-7","volume":"46","author":"LZ Benet","year":"2019","unstructured":"Benet LZ, Bowman CM, Koleske ML, Rinaldi CL, Sodhi JK. Understanding drug-drug interaction and pharmacogenomic changes in pharmacokinetics for metabolized drugs. J Pharmacokinet Pharmacodynam. 2019;46:155\u201363.","journal-title":"J Pharmacokinet Pharmacodynam"},{"issue":"9","key":"3105_CR21","doi-asserted-by":"publisher","first-page":"819","DOI":"10.2165\/00003088-200342090-00003","volume":"42","author":"M Niemi","year":"2003","unstructured":"Niemi M, Backman JT, Fromm MF, Neuvonen PJ, Kivist\u00f6 KT. Pharmacokinetic interactions with rifampicin. Clin Pharmacokinet. 2003;42(9):819\u201350.","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"3105_CR22","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/clpt.2010.271","volume":"89","author":"M Reitman","year":"2011","unstructured":"Reitman M, Chu X, Cai X, Yabut J, Venkatasubramanian R, Zajic S, et al. Rifampin\u2019s acute inhibitory and chronic inductive drug interactions: experimental and model-based approaches to drug\u2013drug interaction trial design. Clin Pharmacol Ther. 2011;89(2):234\u201342.","journal-title":"Clin Pharmacol Ther"},{"key":"3105_CR23","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/clpt.2008.186","volume":"85","author":"HX Zheng","year":"2009","unstructured":"Zheng HX, Huang Y, Frassetto LA, Benet LZ. Elucidating rifampin\u2019s inducing and inhibiting effects on glyburide pharmacokinetics and blood glucose in healthy volunteers: Unmasking the differential effects of enzyme induction and transporter inhibition for a drug and its primary metabolite. Clin Pharmacol Ther. 2009;85:78\u201385.","journal-title":"Clin Pharmacol Ther"},{"key":"3105_CR24","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1208\/s12248-019-0373-3","volume":"21","author":"LZ Benet","year":"2019","unstructured":"Benet LZ, Bowman CM, Sodhi JK. How transporters have changed basic pharmacokinetic understanding. AAPS J. 2019;21:103.","journal-title":"AAPS J"},{"issue":"4","key":"3105_CR25","first-page":"478","volume":"16","author":"A Soldner","year":"1999","unstructured":"Soldner A, Christians U, Susanto M, Wacher VJ, Silverman JA, Benet LZ. Grapefruit juice activates P-glycoprotein-mediated drug transport. 1999;16(4):478\u201385.","journal-title":"Grapefruit juice activates P-glycoprotein-mediated drug transport"},{"key":"3105_CR26","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1124\/dmd.104.002337","volume":"33","author":"H Satoh","year":"2005","unstructured":"Satoh H, Yamashita F, Tsujimoto M, Murakami H, Koyabu N, Ohtani H, Sawada Y. Citrus juices inhibit the function of human organic anion-transporting polypeptide OATP-B. Drug Metab Dispos. 2005;33:518\u201323.","journal-title":"Drug Metab Dispos"},{"key":"3105_CR27","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/sj.clpt.6100104","volume":"81","author":"DG Bailey","year":"2007","unstructured":"Bailey DG, Dresser GK, Leake BF, Kim RB. Naringin is a major and selective clinical inhibitor of organic anion-transporting polypeptide 1A2 (OATP1A2) in grapefruit juice. Clin Pharmacol Ther. 2007;81:495\u2013502.","journal-title":"Clin Pharmacol Ther"},{"key":"3105_CR28","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1111\/1750-3841.15096","volume":"85","author":"Z-T Wang","year":"2020","unstructured":"Wang Z-T, Xue Y, Sun H, Zhang Z, Tang Z-J, Liu S-B, Cai W-M. Effect of tea polyphenols on the oral and intravenous pharmacokinetics of ticagrelor in rats and its in vitro metabolism. J Food Sci. 2020;85:1285\u201391.","journal-title":"J Food Sci"}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-021-03105-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11095-021-03105-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-021-03105-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,18]],"date-time":"2021-11-18T18:26:53Z","timestamp":1637260013000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11095-021-03105-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":28,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["3105"],"URL":"https:\/\/doi.org\/10.1007\/s11095-021-03105-w","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"value":"0724-8741","type":"print"},{"value":"1573-904X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"21 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}